{"id":"https://openalex.org/W4240429779","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.99","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","display_name":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","publication_year":2012,"publication_date":"2012-09-20","ids":{"openalex":"https://openalex.org/W4240429779","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.99"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.27_suppl.99","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.99","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.27_suppl.99","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035606711","display_name":"Francis P. Arena","orcid":"https://orcid.org/0000-0002-7215-2551","observed_orcids":["https://orcid.org/0000-0002-7215-2551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francis P. Arena","raw_affiliation_strings":["Arena Oncology Associates, Lake Success, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arena Oncology Associates, Lake Success, NY","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111994366","display_name":"Shinzaburo Noguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shinzaburo Noguchi","raw_affiliation_strings":["Osaka University, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University, Osaka, Japan","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049907389","display_name":"Kathleen I. Pritchard","orcid":"https://orcid.org/0000-0003-0758-9666","observed_orcids":["https://orcid.org/0000-0003-0758-9666"]},"institutions":[{"id":"https://openalex.org/I1323843004","display_name":"Sunnybrook Health Science Centre","ror":"https://ror.org/03wefcv03","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004"]},{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4405271711","display_name":"Odette Cancer Centre","ror":"https://ror.org/02ww1s787","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1323843004","https://openalex.org/I4405271711"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Kathleen I. Pritchard","raw_affiliation_strings":["Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada","institution_ids":["https://openalex.org/I1323843004","https://openalex.org/I185261750","https://openalex.org/I4405271711"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072308451","display_name":"Howard A. Burris","orcid":"https://orcid.org/0000-0002-1501-2931","observed_orcids":["https://orcid.org/0000-0002-1501-2931"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard A. Burris","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hope S. Rugo","raw_affiliation_strings":["University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025718393","display_name":"Michael Gnant","orcid":"https://orcid.org/0000-0003-1002-2118","observed_orcids":["https://orcid.org/0000-0003-1002-2118"]},"institutions":[{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Michael Gnant","raw_affiliation_strings":["Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria","institution_ids":["https://openalex.org/I76134821"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018617106","display_name":"Gabriel N. Hortob\u00e1gyi","orcid":"https://orcid.org/0000-0002-4873-4412","observed_orcids":["https://orcid.org/0000-0002-4873-4412","https://orcid.org/0000-0001-9030-4136"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel N. Hortobagyi","raw_affiliation_strings":["University of Texas M. D. Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M. D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045839302","display_name":"Luciano Latini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403386718","display_name":"Ospedale di Macerata","ror":"https://ror.org/019jb9m51","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4403386718"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Luciano Latini","raw_affiliation_strings":["Hospital of Macerata, Macerata, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital of Macerata, Macerata, Italy","institution_ids":["https://openalex.org/I4403386718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022422153","display_name":"Denise Aysel Yardley","orcid":"https://orcid.org/0000-0002-8664-3458","observed_orcids":["https://orcid.org/0000-0002-8664-3458","https://orcid.org/0009-0008-1720-6183"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denise Aysel Yardley","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009523282","display_name":"Bohuslav Melichar","orcid":"https://orcid.org/0000-0002-5474-6866","observed_orcids":["https://orcid.org/0000-0002-5474-6866"]},"institutions":[{"id":"https://openalex.org/I70703428","display_name":"Palack\u00fd University Olomouc","ror":"https://ror.org/04qxnmv42","country_code":"CZ","type":"education","lineage":["https://openalex.org/I70703428"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Bohuslav Melichar","raw_affiliation_strings":["Palacky University Medical School, Olomouc, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Palacky University Medical School, Olomouc, Czech Republic","institution_ids":["https://openalex.org/I70703428"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073756616","display_name":"Katar\u00edna Petr\u00e1kov\u00e1","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115043","display_name":"Masaryk Memorial Cancer Institute","ror":"https://ror.org/0270ceh40","country_code":"CZ","type":"facility","lineage":["https://openalex.org/I4210115043"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Katarina Petrakova","raw_affiliation_strings":["Masaryk Memorial Cancer Institute, Brno, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Masaryk Memorial Cancer Institute, Brno, Czech Republic","institution_ids":["https://openalex.org/I4210115043"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967040","display_name":"Wael A. Harb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131576","display_name":"Horizon Oncology Center","ror":"https://ror.org/03ambf510","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210131576"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wael Harb","raw_affiliation_strings":["Horizon Oncoloy Center, Lafayette, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Horizon Oncoloy Center, Lafayette, IN","institution_ids":["https://openalex.org/I4210131576"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063479774","display_name":"Wentao Feng","orcid":"https://orcid.org/0000-0001-8109-5117","observed_orcids":["https://orcid.org/0000-0001-8109-5117"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wentao Feng","raw_affiliation_strings":["Novartis Pharmaceuticals, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Hanover, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049999075","display_name":"Ayelet Cahana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayelet Cahana","raw_affiliation_strings":["Novartis Pharmaceuticals, Florham Park, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Florham Park, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073277448","display_name":"Tanya Taran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya Taran","raw_affiliation_strings":["Novartis Pharmaceuticals, Florham Park, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, Florham Park, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071553983","display_name":"Mario Campone","orcid":"https://orcid.org/0000-0002-5196-5908","observed_orcids":["https://orcid.org/0000-0002-5196-5908"]},"institutions":[{"id":"https://openalex.org/I4210106090","display_name":"Institut de Canc\u00e9rologie de l'Ouest","ror":"https://ror.org/01m6as704","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210106090"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Mario Campone","raw_affiliation_strings":["Institut de Canc\u00e9rologie de l\u2019Ouest - Ren\u00e9 Gauducheau, Nantes Saint Herblain, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Canc\u00e9rologie de l\u2019Ouest - Ren\u00e9 Gauducheau, Nantes Saint Herblain, France","institution_ids":["https://openalex.org/I4210106090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jos\u00e9 Baselga","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027944082","display_name":"Tarek Sahmoud","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tarek Sahmoud","raw_affiliation_strings":["Novartis Pharmaceuticals, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Hanover, NJ","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103604149","display_name":"David Edward Lebwohl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Edward Lebwohl","raw_affiliation_strings":["Novartis Pharmaceuticals, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Hanover, NJ","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087380706","display_name":"Martine J Piccart","orcid":"https://orcid.org/0000-0001-9068-8504","observed_orcids":["https://orcid.org/0000-0001-9068-8504"]},"institutions":[{"id":"https://openalex.org/I2801838318","display_name":"Institut Jules Bordet","ror":"https://ror.org/05e8s8534","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801838318"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Martine J. Piccart-Gebhart","raw_affiliation_strings":["Jules Bordet Institute, Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jules Bordet Institute, Brussels, Belgium","institution_ids":["https://openalex.org/I2801838318"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"27_suppl","first_page":"99","last_page":"99"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9990000128746033},{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.8360000252723694},{"id":"https://openalex.org/keywords/postmenopausal-women","display_name":"postmenopausal women","score":0.9459999799728394},{"id":"https://openalex.org/keywords/advanced-breast-cancer","display_name":"advanced breast cancer","score":0.9020000100135803},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.7250000238418579},{"id":"https://openalex.org/keywords/exemestane","display_name":"exemestane","score":0.9909999966621399},{"id":"https://openalex.org/keywords/aromatase-inhibitor-resistance","display_name":"aromatase inhibitor resistance","score":0.8050000071525574},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9319999814033508},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.984000027179718},{"id":"https://openalex.org/keywords/bolero-2-trial","display_name":"BOLERO-2 trial","score":0.9470000267028809},{"id":"https://openalex.org/keywords/letrozole","display_name":"letrozole","score":0.7390000224113464},{"id":"https://openalex.org/keywords/anastrozole","display_name":"anastrozole","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5669999718666077},{"id":"https://openalex.org/keywords/bone-turnover","display_name":"bone turnover","score":0.8870000243186951},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.5860000252723694},{"id":"https://openalex.org/keywords/endocrine-resistance","display_name":"endocrine therapy resistance","score":0.4659999907016754},{"id":"https://openalex.org/keywords/combination-targeted-therapy","display_name":"combination targeted therapy","score":0.35600000619888306},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.453000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8867546319961548},{"id":"https://openalex.org/C2775860665","wikidata":"https://www.wikidata.org/wiki/Q418819","display_name":"Exemestane","level":5,"score":0.8270492553710938},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.7866412401199341},{"id":"https://openalex.org/C2776215463","wikidata":"https://www.wikidata.org/wiki/Q419143","display_name":"Anastrozole","level":5,"score":0.7006734609603882},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.684869647026062},{"id":"https://openalex.org/C2778504769","wikidata":"https://www.wikidata.org/wiki/Q3040305","display_name":"Aromatase inhibitor","level":5,"score":0.5999654531478882},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5976856350898743},{"id":"https://openalex.org/C2778812593","wikidata":"https://www.wikidata.org/wiki/Q194974","display_name":"Letrozole","level":5,"score":0.5405060648918152},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5374394655227661},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.5134423971176147},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5113541483879089},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.5007107257843018},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48029014468193054},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.42238110303878784},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36830538511276245},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.35685938596725464},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.26867711544036865},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.17521068453788757},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.13352560997009277},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.27_suppl.99","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.99","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.27_suppl.99","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2063538932","https://openalex.org/W2999892282","https://openalex.org/W2151082560","https://openalex.org/W2031131661","https://openalex.org/W2977259025","https://openalex.org/W2461531801","https://openalex.org/W2879955921","https://openalex.org/W2021129463","https://openalex.org/W2022630638","https://openalex.org/W2020725023"],"abstract_inverted_index":{"99":[0],"Background:":[1],"Current":[2],"treatment":[3,161],"options":[4],"for":[5,260],"postmenopausal":[6,94],"patients":[7,289,300],"with":[8,96,176,201,223,239,257,290],"estrogen-receptor\u2013positive":[9,98,293],"breast":[10],"cancer":[11,155],"(BC)":[12],"who":[13],"relapse":[14],"or":[15,101,106,116],"progress":[16],"on":[17,312],"a":[18,69],"nonsteroidal":[19],"aromatase":[20,46],"inhibitor":[21,47],"(NSAI)":[22],"are":[23,64],"limited.":[24],"The":[25,120],"BOLERO-2":[26,67],"trial":[27,75],"supports":[28],"the":[29,44,308],"activity":[30],"of":[31,38,310],"everolimus":[32],"(EVE;":[33],"an":[34],"oral":[35],"mammalian":[36],"target":[37],"rapamycin":[39],"[mTOR]":[40],"inhibitor)":[41],"added":[42],"to":[43,50,112,283],"steroidal":[45],"exemestane":[48],"(EXE)":[49],"prolong":[51],"progression-free":[52],"survival":[53,62,137],"(PFS)":[54],"in":[55,93,190,288],"this":[56],"patient":[57],"population.":[58],"Long-term":[59],"PFS":[60,124,167,194,263,287],"and":[61,142,153,170,215,230,271,274,303],"data":[63,264,276],"awaited.":[65],"Methods:":[66],"is":[68],"phase":[70],"3,":[71],"double-blind,":[72],"randomized,":[73],"international":[74],"comparing":[76],"EVE":[77,113,177,224,240,282,311],"(10":[78],"mg":[79,85],"once":[80,86],"daily)":[81,87],"+":[82,91,114,118,178,185,203,225,241,246],"EXE":[83,92,115,179,186,204,226,242,247,284],"(25":[84],"vs.":[88],"placebo":[89],"(PBO)":[90],"women":[95],"advanced":[97,292],"BC":[99],"progressing":[100],"recurring":[102],"after":[103],"NSAIs":[104],"(letrozole":[105],"anastrozole).":[107],"Patients":[108],"were":[109,157,173,237,255,296],"randomized":[110],"(2:1)":[111],"PBO":[117,184,202,245],"EXE.":[119],"primary":[121],"endpoint":[122],"was":[123,168,198],"by":[125,195],"local":[126,196],"investigator":[127],"assessment.":[128],"Main":[129],"secondary":[130],"endpoints":[131],"included":[132],"centrally":[133],"assessed":[134],"PFS,":[135],"overall":[136,143],"(OS),":[138],"safety,":[139],"bone":[140],"turnover,":[141],"response":[144,171],"rate.":[145],"Results:":[146],"Baseline":[147],"disease":[148],"characteristics":[149],"including":[150,265],"tumor":[151],"burden":[152],"prior":[154],"therapy":[156],"well":[158],"balanced":[159],"between":[160],"arms":[162],"(N":[163],"=":[164,181,188],"724).":[165],"Median":[166,193],"doubled":[169],"rates":[172],"consistently":[174],"improved":[175],"(n":[180,187],"485)":[182],"vs":[183,205,244],"239)":[189],"interim":[191],"analyses.":[192],"assessment":[197],"~3":[199],"mo":[200,207,217,229,232,251],"6.9":[206],"(hazard":[208],"ratio":[209],"[HR],":[210],"0.43;":[211],"P":[212,220],"<":[213,221],".0001)":[214,222],"7.4":[216],"(HR,":[218],"0.44;":[219],"at":[227,249],"7.5":[228],"12.5":[231,250],"follow-up,":[233],"respectively.":[234],"Fewer":[235],"deaths":[236,298],"reported":[238],"(17.2%)":[243],"(22.7%)":[248],"follow-up.":[252],"Safety":[253],"profiles":[254],"consistent":[256],"previous":[258],"reports":[259],"mTOR":[261],"inhibitors.":[262],"528":[266],"events":[267],"(protocol-specified":[268],"final":[269],"analysis),":[270],"updated":[272],"OS":[273],"safety":[275],"will":[277,306],"be":[278],"presented.":[279],"Conclusions:":[280],"Adding":[281],"markedly":[285],"prolonged":[286],"NSAI-refractory":[291],"BC.":[294],"There":[295],"fewer":[297],"among":[299],"receiving":[301],"EVE,":[302],"further":[304],"follow-up":[305],"evaluate":[307],"effect":[309],"OS.":[313]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2022-05-12T00:00:00"}